‘Best way to share knowledge in a rapidly-evolving field’, ‘Useful to improve patient care’, ‘Accurate & concise information’: @martatapia1, Javier Cortes MD PhD, Laura Moliner & P. Rutkowski,on why they contribute to and/or read #ESMOBooks 🔗ow.ly/CJzk50RU63l

Ivana Božović

There is still time to join this expert exchange and share knowledge with the experts in metastatic #breastcancer .

Register now and join the conversation: 🔗ow.ly/bcZJ50RIwVU

The names of the candidates running for the ESMO Presidency 2027-2028 have been announced. Find out more about the candidates.
📌 ow.ly/4Uku50RSIJL

Super #ESMOYOC meeting to plan future exciting activities for ESMO - Eur. Oncology young members: so privileged to work with such brilliant minds ❤️Maria Kfoury Pablo Mando Rille Rodrigo Sánchez-Bayona Elene Mariamidze Myrto K. Moutafi Liz Connolly Pawel Sobczuk Hongcheng Zhu 祝鸿程 Deniz Can Guven Emre Kocakavuk, MD, PhD

Some of the many highlights of #ESMOBreast24
🗝️DOLAF trial and its interesting hypothesis of combining PARPi and ET and IO
🗝️ T-DXd retreatment safety after G1 ILD
🗝️ Growth in data of fertility related topics in young BRCA patients
🗝️ Sexual health in the center of the stage

#ESMOBreast24 #ESMOAmbassadors
🔑🚫Primary outcome in IMpassion132 highlights unmet need for early relapsing #TNBC
🔑Emerging data from ADC-IO combinations
🔑Safety and #QoL updates for new 💊capivasertib and 💉datopotamab
🔑📈Body of evidence for new biomarkers 🎯such as HER2Dx

#ESMOBreast24 : Atezolizumab + sacituzumab govitecan show encouraging activity in inoperable #TNBC . Efficacy & safety of the first-line novel combination were assessed in patients w/ untreated PD-L1 positive locally advanced or metastatic tumours.
👉 ow.ly/AFI750RQJuJ

Early recurrent TNBC represents a major unmet need in breast oncology, with unfortunately no added benefit from PD-L1 inhibition added to chemotherapy.

Novel ADCs are being evaluated in this population, with great hopes for improved outcomes.

#ESMOBreast24 #ESMOAmbassadors

Important data at #ESMOBreast14 in #survivorship field including safety of vaginal estrogen therapy for selected patients, physical exercise in advanced disease and fertility techniques in #BRCA carriers (personal COI here)…what a fantastic event!!!

ESMO - Eur. Oncology #ESMOAmbassadors

The clock is ticking…only 34 days left until we welcome you for the ESMO - Eur. Oncology Gastrointestinal Cancers Congress 2024 in beautiful Munich.

#ESMOGI24

This is going to be fun🤩

✅Two very interesting cases
🚀Two bright young colleagues presenting

and Myrto K. Moutafi running the show…what can go wrong?

Do not miss the chance to attend the upcoming YO4YO Clinical Case Discussion where Ben Westphalen, Myrto K. Moutafi, Erman Akkus and Paolo D’arienzo will discuss how to approach a genomic profiling report for choosing the next line of therapy.
📌ow.ly/BoLO50RP7H1

What will be the future treatment algorithm of metastatic ER+/HER2- MBC?
🔹Novel endocrine therapies are in phase 3 studies alone and in combination
🔹Novel targeted therapies are investigated
🔹ADCs are advancing to earlier lines
🔹Relapses after adjuvant CDK4/6i
#ESMOBreast24

ESMO - Eur. Oncology Preceptorship and educational opportunities are crucial and valuable for the development of fellows throughout their training process. All these opportunities are extremely important for the advancement of global oncology.
FabriceAndre Andres Cervantes Toni Choueiri, MD

Updated 📢 #RenalCellCarcinoma : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data for first-line metastatic trials as well as sequencing strategies & new agents such as belzutifan. ow.ly/nZA050RP77l
#kcsm @silke_gillessen

Enhance your ESMO membership! Register now to delve into #BreastCancer knowledge and engage with experts in real-time. Don't miss out on staying informed and connected.
Register now: 🔗ow.ly/Fc2e50RJPUq
#ESMODeepDive

#ESMOBreast24 : phase II data shows promising results for combining olaparib, durvalumab, and fulvestrant in treating #mBC w/ BRCA1/2 mutations. This novel combination holds great promise for BRCA-mutated #mbc .

#ESMODailyReporter 📌ow.ly/Jt5n50ROCTY

#ESMOGynae24 : Explore cutting-edge research, exchange insights with leading experts, & elevate yr practice with up-to-date knowledge in the field. Register until 22 May to get advantageous fees.
📅 20-22 June 2024 📍Location: Florence, Italy

🔗ow.ly/qGF950Rmiwm

#ESMOBreast24 : What do you find the most relevant #ScientificAdvancements in #OncologyResearch ? Share the newest findings that you consider having the potential to improve #CancerCare in #bcsm . #BreastCancer #ESMOAmbassadors

👉You can still join the experts evaluating the latest, practice-changing manuscripts on #NSCLC , urothelial cancer and early #breastcancer . Take part in the discussion with your ESMO membership: 🔗ow.ly/beIu50Rxriw
Evandro de Azambuja, MD, PhD Benjamin Besse Patrizia Giannatempo